Welcome to Grünenthal's Press Centre

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

You’d like to know more about Grünenthal?

In this section you will find both current and archived press releases as well as background information and a selection of images. All of these are downloadable.

If you have any further questions, please do not hesitate to contact us.